NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Arivin Therapeutics

Arivin Therapeutics

Private
HelsinkiHealthcare & Life Scienceshttps://arivintx.com/

Last Round

Grant

Jan 22, 2026

Total Funding Raised

$3.51M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Arivin Therapeutics is a biotechnology company that develops antimicrobial therapies to treat drug-resistant bacterial infections by targeting bacterial toxins and biofilms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antimicrobial therapydrug discoveryantimicrobial resistanceAMRsuperbug treatmentbacterial virulencebiofilm disruptionbiotechnologyrespiratory infectioncystic fibrosisCFnon-cystic fibrosis bronchiectasisNCFBinhalation therapysmall moleculeclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Arivin Therapeutics Comparables

Compare Arivin Therapeutics with similar companies based on industry and business-model similarity.

Arivin Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Zaluvida Ventures
80%
ProclaRx LLC
79%
AlgiPharma AS
79%

Arivin Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJan 22, 2026
SeedAug 28, 2025
AcceleratorJan 27, 2022

Arivin Therapeutics Investors

Notable investors and investment history

Arivin Therapeutics investors
InvestorRounds
SPARK FinlandAccelerator
INCATEAccelerator
Business FinlandGrant, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 18, 2026

    Monthly visitors increased 349% MoM.

  • Jan 22, 2026

    $440K grant received from Business Finland.

Arivin Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Arivin Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Arivin Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersHelsinki
Employee Range10
Year Founded2022
Last FundingJan 22, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.